Akeso stock
Price history
−49.87% over the period1 year: from $113.10 (November 20, 2025) to $56.70 (November 20, 2026), −49.87%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $56.70 |
| October 30, 2026 | $81.50 |
| September 30, 2026 | $108.70 |
| August 31, 2026 | $89.90 |
| July 31, 2026 | $93.95 |
| June 30, 2026 | $88.05 |
| May 29, 2026 | $118.10 |
| April 30, 2026 | $135.80 |
| March 31, 2026 | $130.20 |
| February 27, 2026 | $106.90 |
| January 30, 2026 | $110.40 |
| December 31, 2025 | $113.10 |
| November 28, 2025 | $122.90 |
| November 20, 2025 | $113.10 |
At a glance
The company
Research, develop, manufacture and commercialize antibody drugs for cancer, cardiovascular and inflammatory diseases
Latest results
Quarter to June 30, 2026 · EPS -¥0.46
TickerLandia's take on Akeso
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−63.65% from the 52-week high
Analysts · 23 analysts
Average target$138.56+144.38% vs. price
Buy 21 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: Akeso
Compared with similar companies: very weak momentum and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh66
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 15.5 68 Price/book 5.24 49 Forward P/E 45.4 81 Profitabilitylow26
How much it earns on revenue and capital.
Metric Value Position in group Operating margin −30.7% 24 Net margin −28.0% 19 ROA −4.5% 25 Gross margin 73.6% 43 ROE −13.6% 20 Earnings stabilitylow29
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 259.7% 27 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthaverage58
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −27.85% 40 Revenue growth (year over year) +27.90% 60 Average revenue growth (3 years) +53.95% 73 Financial strengthlow34
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −7.59 19 Debt/equitycounts in reverse: lower means more financial strength 0.60 19 Current ratio 4.01 63 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak7
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) −43.57% 6 Distance from 200-day average −45.19% 7 Relative strength (3 months) −30.76% 10 1-year return −49.87% 4 Riskvery high87
How much the price swings.
Metric Value Position in group Volatility (60 days) 90.2% 96 Beta (1 year) 1.33 78 Maximum drawdown (12 months) 62.5% 87
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Akeso is pricier than similar companies
Akeso's Forward P/E: 45.4, +43% against the median of a group of 10 similar companies (31.7).
Compared with 10 similar companies
| Metric | Akeso | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 45.4 | High | |
| Operating margin | -30.7% | Low | |
| ROE | -13.6% | Low | |
| Debt/equity | 0.60 | High | |
| Price/book | 5.24 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Akeso. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥1.81B
Latest quarter · Q2 2026
Net income
-¥424.22M
Latest quarter · Q2 2026
Quarterly net margin
-23.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $53.36B
- EPS
- -$1.17
- Volume
- 17.83M
- Daily trading
- €125.28M
- Dividend yield
- 0.00%
How Akeso is changing
All resultsRevenue grew 53.9% a year on average over the last 3 years
Operating margin rose from −183.6% to −32.5%
Shares outstanding up 43.6% in 5 years
Returns
Akeso returns
$1,000 invested in Akeso 5 years ago, on November 22, 2021, would be worth $1,105 today: +10.53% in total, +2.02% per year. This is the price return only: dividends are excluded.
| Period | Akeso | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −37.96% | −6.10% | $620 |
| 6 months | −50.70% | −12.63% | $493 |
| Year to date | −49.87% | −12.56% | $501 |
| 1 year | −49.87% | −13.26% | $501 |
| 3 years | +23.39% | +26.06% | $1,234 |
| 5 years | +10.53% | −10.18% | $1,105 |
Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Akeso: technical analysis
Akeso is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 67.9% below its all-time closing high ($176.90, August 22, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 26
- Below 30: a strong fall in a short time
- vs 200-session average
- −45.19%
Active signals
RSI below 30: the stock has fallen a lot in a short time.
since November 16, 2026
Support and resistance
Price areas where Akeso has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$91.68+61.69%5 touches, last on November 10, 2026
- Resistance$86.35+52.29%2 touches, last on September 1, 2026
- Resistance$81.52+43.78%2 touches, last on June 22, 2026
- Last price$56.70
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.33
- Volatility (60 sessions, annualised)
- 90.2%
- Largest fall in the last year
- −62.45%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Akeso: seasonality
Average monthly price change over 7 years
Over the last 7 years, the strongest month for Akeso has been November: +10.22% on average, positive in 6 years out of 6. The weakest has been May: −2.13% on average, positive in 2 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.35% | −1.11% | 3 of 6 |
| February | +1.82% | −3.12% | 2 of 6 |
| March | +0.69% | +0.02% | 3 of 6 |
| April | +4.15% | +5.18% | 5 of 6 |
| May | −2.13% | −2.84% | 2 of 7 |
| June | +7.79% | +1.29% | 4 of 7 |
| July | +8.49% | +6.70% | 4 of 7 |
| August | −1.28% | −4.06% | 3 of 7 |
| September | +6.09% | +4.50% | 4 of 7 |
| October | +0.37% | −8.45% | 3 of 7 |
| November | +10.22% | +10.97% | 6 of 6 |
| December | +2.90% | −7.45% | 2 of 6 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Akeso and its competitors
Based in Zhongshan, China, Akeso, Inc. was founded in 2012 and develops antibody drugs for cancer and immune-related diseases. Its research, development, manufacturing and commercialization activities cover markets worldwide. The pipeline centers on bispecific antibodies, including AK104, a PD-1/CTLA-4 candidate for cervical, gastric, lung and liver cancers, and AK112, a PD-1/VEGF candidate for several solid tumors. Other programs include AK117, a CD47 antibody for hematologic cancers, and AK101, AK111, AK120 and AK102, targeting psoriasis, ulcerative colitis, ankylosing spondylitis, atopic dermatitis and hypercholesterolemia.
- Headquarters
- Zhongshan, China
- Employees
- 4,082
- Founded
- 2012
- Chief executive
- Yu Xia
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Akeso9926 | $6.81B | -30.7% | — | −50.70% |
| Genscript Biotech1548 | $8.77B | 14.9% | — | +112.07% |
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
| ALTEOGEN196170 | $9.05B | 47.2% | 97.1 | −36.93% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
| Pharmaron Beijing300759 | $10.59B | 14.0% | 39.3 | +44.36% |
Same industry or related industries, similar size. Compare Akeso with its competitors · Full profile
